Copyright © EndoSphere Inc. 2006-2019  

All Rights Reserved.

 
 
Using the body's natural physiology
EndoSphere, a US-based medtech company, has developed a novel category of non-invasive endoscopic therapies targeting gastrointestinal (GI) disorders and metabolic diseases.
 
The Endosphere portfolio includes a product for treating Obesity and a pipeline w ith potential therapies for Non-alcoholic Fatty Liver Disease, Type 2 Diabetes, and Drug Compliance.
 
 
EndoSphere's patented "EndoMetabolic" devices are designed to complement, facilitate, recalibrate, and amplify the natural physiological responses to food ingestion in order to restore the normal functions of the Duodenum, the organ recognized as the body's Metabolic Control Center.  The Duodenum plays important roles in satiety regulation, insulin management, metabolic feedback loops, digestion, and drug delivery.  
 

A New Paradigm for Treating Obesity

EndoSphere's new "EndoMetabolic" devices treat metabolic disease endoscopically without the need for surgery or weight-loss drugs. Unlike restrictive devices and bariatric surgeries, this new device category works with the body's natural physiology, not against it -- representing a new era of physiological-amplifying, hormonal-regulating, and satiety-inducing device therapies

 

EndoSphere's flagship Obesity device is reversible, repeatable, and incisionless. CE Mark regulatory approval was granted for the original device in 2012. An enhanced version has now been developed and is in the pivotal stage of clinical testing

How it works:

As ingesta passes through the GI tract, EndoSphere's Obesity device causes ingesta to have more contact with the neuron-lined walls of the Duodenum. This extra stimulation accelerates the body's natural physiological responses during meals -- tricking the body to feel full faster, stay satisfied longer, and reduce the urge to over-eat

 

News & Industry Recognitions

What's the Right Way to Reverse the Obesity Epidemic?

The New York Times - September 17, 2019.  The worldwide obesity rate has nearly tripled since 1975, according to the World Health Organization, but the problem is particularly acute in the United States: 39.8 percent of adults were obese in 2016, compared with only 15 percent in the late 1970s, according to the federal Centers for Disease Control and Prevention, the highest rate of any developed country. Obesity, the CDC says, is associated with increased risk for leading causes of death, including diabetes, heart disease, stroke and some types of cancer. In fact, a Columbia University study in 2013 found that obesity is far more deadly than was previously thought, accounting for nearly one in every five deaths among Americans between ages 40 and 85.

EndoSphere receives top industry recognition, named to "Fierce 15" list of the world's most promising privately-held medical technology companies

Boston, MA - October 03, 2012.  EndoSphere today received top industry recognition, named to the inaugural "Fierce 15 List" of the world's 15 most promising privately-held medical tehnology companies, named by industry research and media firm FierceMedicalDevices. According to FierceMedicalDevices, EndoSphere was named to the Fierce 15 list based, in part, on its creativity and game-changing innovations in the industry. Editor Damian Garde said, “EndoSphere’s exciting device, the Satisphere™ System, presents a non-surgical solution for the millions of people struggling to lose weight, demonstrating to be less invasive than bariatric surgery and more effective than diet and exercise.”

EndoSphere's next-generation endoscopic device receives CE Mark regulatory approval

 

Columbus, OH - April 27, 2012.  EndoSphere Inc. today announced that it received CE Mark regulatory approval for the Satisphere™ System, a noninvasive device for the treatment for obesity – one of the world’s largest health issues. The Satisphere device improves regulation of appetite and satiety by using the body’s natural physiology. The endoscopically-insertable device is completely incisionless, reversible, and repeatable.

EndoSphere receives Innovation Award of $1 million to advance platform of next-generation endoscopic medical devices

Columbus, OH - April 19, 2012.  EndoSphere today announced that the Ohio Department of Development's Innovation Fund has awarded $1 million to support EndoSphere’s platform of non-invasive, endoscopically-implantable devices that treat metabolic diseases including obesity and type 2 diabetes.

EndoSphere receives pivotal patent approval by USPTO; Wins broad coverage of claims relating to its breakthrough endoscopic technology for treating obesity

Columbus, Ohio - June 15, 2011. EndoSphere Inc., a medical technology company that holds 23 U.S. and international issued and pending patents, announced today that the U.S. Patent and Trademark Office has issued the company a patent covering the use of its endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes.

Broadline Capital leads EndoSphere's Series A preferred financing round

Columbus, Ohio - June 1, 2011.  EndoSphere Inc., a medical technology company developing a platform of endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes, announced today the completion of an oversubscribed Series A Preferred Financing round led by Broadline Capital, a global private equity investment firm.  EndoSphere holds numerous U.S. and international issued and pending patents, and plans to use the funding to expand its intellectual property assets and to complete additional clinical product testing.

 

Keynote by

Dr. Kenneth Binmoeller

Want to learn more about the "EndoMetabolic" science behind Endosphere's novel device technology?  Click here to view excerpts from a keynote address by Dr. Kenneth Binmoeller (EndoSphere's Founder & Chief Scientific Officer), presented at an international medical conference